natgillin/translations-raw huggingface dataset:
However, the CMDh considered that additional changes were necessary to the wording proposed for the Summary of Product Characteristics (SmPC) and the Package Leaflet, to provide appropriate guidance on the recommendation regarding the maximum daily dose in children and adolescents over 40 kg of body weight but below 18 years of age.
Vendar pa je menila, da so potrebne dodatne spremembe predlaganega besedila povzetka glavnih značilnosti zdravila in navodila za uporabo za zagotovitev ustreznih smernic v zvezi s priporočili o najvišjem dnevnem odmerku pri otrocih in mladostnikih, mlajših od 18 let, s telesno maso nad 40 kg. Skupina CMDh je upoštevala, da farmakokinetični podatki, ki so bili pregledani med postopkom, kažejo, da se razpolovna doba hidroksizina verjetno linearno povečuje z leti (razpolovna doba pri otrocih, starih 12 mesecev, je štiri ure, pri otrocih, starih 14 let, 11 ur, pri odraslih 14 ur, pri starejših pa 29 ur).
Route of administration Packaging Content
Vsebina Navedenih pakiranj
EU Number Invented name Strength Pharmaceutical form
Izmišljeno ime Jakost
Package size l t o r
1 vial o ā
No special precautions are required.
Ni posebnih previdnostnih ukrepov.
This summary was last updated in March 2017.
Povzetek je bil nazadnje posodobljen marca 2017.
These studies were performed under laboratory as well as under typical European farming conditions.
Te študije so bile izvedene v laboratorijskih pogojih in v pogojih značilnega evropskega kmetovanja.
This medicine is the same as Ingelvac CircoFLEX, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Ingelvac CircoFLEX, ki je že odobreno v Evropski uniji (EU).
The vaccine starts to be effective 2 weeks after vaccination and protection lasts for 17 weeks.
Učinkovati začne dva tedna po cepljenju, zaščita pa traja 17 tednov po cepljenju.
This active immune response will help to protect the pig against the disease caused by this virus.
Aktivni imunski odziv lahko prispeva k zaščiti prašiča pred boleznijo, ki jo ta virus povzroča.
It is given by injection into the muscle as a single dose.
Daje se z injiciranjem v mišico v enkratnem odmerku.
The full EPAR for Ingelvac PCV Flex can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila Ingelvac PCV Flex je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Ingelvac PCV FLEX's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Ingelvac PCV Flex večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
When a pig is given the vaccine, the pig's immune system recognises the protein as ‘foreign' and reacts by building up an active immune response.
Ko prašič prejme cepivo, imunski sistem živali prepozna beljakovino iz virusa kot „tujek“ ter se nanj odzove tako, da sproži aktivni imunski odziv.
The most common side effect with Ingelvac PCV Flex (which may affect more than 1 in 10 animals) is a mild and short lived increase in body temperature on the day of vaccination.
Najpogostejši neželeni učinek zdravila Ingelvac PCV Flex (ki lahko prizadene več kot 1 od 10 živali) je blago in kratkotrajno povišanje telesne temperature na dan cepljenja.
In the future, the immune system will be able to react against the virus more quickly when it is exposed to the virus.
Ob ponovni izpostavitvi virusu v prihodnosti bo imunski sistem lahko hitreje reagiral proti njemu.
This is a summary of the European public assessment report (EPAR) for Ingelvac PCV Flex.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ingelvac PCV Flex.
PCV2 infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty breathing, pale skin and jaundice (yellowing of the skin).
Okužbe s PCV2 se kažejo s kliničnimi znaki, kot so zmanjšanje telesne mase ali zastoj rasti, povečane bezgavke, oteženo dihanje, bleda koža in zlatenica (rumeno obarvanje kože).
The European Commission granted a marketing authorisation valid throughout the EU for Ingelvac PCV Flex on 24 May 2017.
Evropska komisija je dovoljenje za promet z zdravilom Ingelvac PCV Flex, veljavno po vsej Evropski uniji, izdala 24/05/2017.
Ingelvac PCV Flex is available as a suspension for injection and can only be obtained with a prescription.
Zdravilo Ingelvac PCV Flex je na voljo v obliki suspenzije za injiciranje in se izdaja le na recept.
The withdrawal period for meat from pigs treated with Ingelvac PCV Flex is ‘zero days', which means there is no mandatory waiting time.
Karenca za meso prašičev, zdravljenih s cepivom Ingelvac PCV Flex, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
For the full list of restrictions and all side effects reported with Ingelvac PCV Flex, see the package leaflet.
Za celoten seznam omejitev in neželenih učinkov, o katerih so poročali pri uporabi zdravila Ingelvac PCV Flex, glejte navodilo za uporabo.
Ingelvac PCV Flex is to be used in pigs which have no maternally derived antibodies (a special type of proteins, received from the mother in the milk that help the body to fight infection) to PCV2.
Zdravilo Ingelvac PCV Flex se uporablja pri prašičih, ki od matere niso prejeli protiteles (posebne vrste beljakovin, prejete od matere prek mleka, ki pomagajo telesu pri borbi z okužbami) proti PCV2.
The trials showed that vaccination of pigs (which had no antibodies to PCV2 before vaccination) with Ingelvac PCV Flex reduced the levels of PCV2 in the blood, clinical signs of PCV2 infection, virus excreted from the nose and death rates.
V njih je bilo dokazano, da se je zaradi cepljenja prašičev (ki pred cepljenjem niso imeli protiteles proti PCV2) z zdravilom Ingelvac PCV Flex znižala raven PCV2 v krvi, zmanjšalo število znakov okužbe s PCV2, zmanjšalo izločanje virusa iz rilca živali in znižala stopnja umrljivosti.
The company that makes Ingelvac CircoFLEX has agreed that its scientific data can be used for Ingelvac PCV Flex (‘informed consent').
Družba, ki proizvaja zdravilo Ingelvac CircoFLEX, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Ingelvac PCV Flex (uporaba dokumentacije s soglasjem).
Ingelvac PCV Flex has been studied in a number of trials involving pigs of various breeds.
Zdravilo Ingelvac PCV Flex je bilo preučeno v več preskušanjih, ki so vključevala prašiče različnih pasem.
For more information about treatment with Ingelvac PCV Flex, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za več informacij o zdravljenju z zdravilom Ingelvac PCV Flex naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For practical information about using Ingelvac PCV Flex, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za praktične informacije o uporabi zdravila Ingelvac PCV Flex naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
Other information about Ingelvac PCV Flex:
Druge informacije o zdravilu Ingelvac PCV Flex:
Ingelvac PCV Flex is a vaccine used to protect pigs from two weeks of age against porcine circovirus type 2 (PCV2).
Ingelvac PCV Flex je cepivo za zaščito prašičev od starosti dveh tednov dalje proti prašičjemu cirkovirusu tipa 2 (PCV2).
Ingelvac PCV Flex is a vaccine.
Zdravilo Ingelvac PCV Flex je cepivo.
Ingelvac PCV Flex contains small amounts of a protein from PCV2.
Zdravilo Ingelvac PCV Flex vsebuje majhne količine beljakovine iz virusa PCV2.
What is Ingelvac PCV Flex and what is it used for?
Kaj je zdravilo Ingelvac PCV Flex in za kaj se uporablja?
Ingelvac PCV Flex porcine circovirus type 2 vaccine
Ingelvac PCV Flex cepivo prašičjega cirkovirusa tipa 2
What benefits of Ingelvac PCV Flex have been shown in studies?
Kakšne koristi je zdravilo Ingelvac PCV Flex izkazalo v študijah?
What are the risks associated with Ingelvac PCV Flex?
Kakšna tveganja so povezana z zdravilom Ingelvac PCV Flex?
Why is Ingelvac PCV Flex approved?
Zakaj je bilo zdravilo Ingelvac PCV Flex odobreno?
Ingelvac PCV Flex contains the active substance porcine circovirus type 2 ORF2 protein.
Zdravilo Ingelvac PCV Flex vsebuje zdravilno učinkovino beljakovino ORF2 prašičjega cirkovirusa tipa 2.
How is Ingelvac PCV Flex used?
Kako se zdravilo Ingelvac PCV Flex uporablja?
How does Ingelvac PCV Flex work?
Kako zdravilo Ingelvac PCV Flex deluje?
It is not intended to provide practical advice on how to use Ingelvac PCV Flex.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Content
Ovojnina
Package size
Vsebina Velikost pakiranja
Invented name Strength Pharmaceutical Form Route of Administration Packaging
Farmacevtska oblika Pot uporabe
EU Number
Številka EU Zaščiteno ime Jakost
This usually takes between 15 and 30 minutes.
Običajno to traja 15 do 30 minut.
Date of first authorisation: 18 December 2007 Date of latest renewal: 20 December 2012
Datum prve odobritve: 18. december 2007 Datum zadnjega podaljšanja: 20. december 2012
Long-term carcinogenicity studies have not been carried out.
Dolgoročnih študij kancerogenosti niso izvedli.
No data are available.
Na voljo ni podatkov.
There are no adequate and well-controlled studies in pregnant women.
Ni zadostnih podatkov in dobro nadziranih študij pri nosečnicah.
These may be more common at the start of treatment.
Lahko so pogostejši ob začetku zdravljenja.
The recommended dosing regimen is described in the following diagram:
Priporočeni režim odmerjanja je opisan v spodnjem diagramu:
D-25436 Uetersen Germany
D-25436 Uetersen Nemčija
Fax: +49 (0) 6101 603-3888
Faks: +49 (0) 6101 603-3888
Additional supportive care should be provided as necessary.
Po potrebi nudimo dodatno podporno oskrbo.
The treatment is divided into two stages: 1.
Zdravljenje poteka v dveh stopnjah: 1.
PRCA causes sudden and severe anaemia.
PRCA povzroča nenadno in hudo anemijo.
Generally, children and adolescents under 30 kg body weight require higher maintenance doses than adults and children over 30 kg.
Na splošno otrocih in adolescenti pod 30 kg potrebujejo višje vzdrževalne odmerke kot odrasli in otroci nad 30 kg.
Contains phenylalanine, see leaflet for further information.
Vsebuje fenilalanin, glej navodilo za uporabo za dodatno informacijo.
Each syringe should be used for a single injection only.
Vsako injekcijsko brizgo se sme uporabiti samo za eno injiciranje.
A systematic review has also been performed involving more than 9 000 cancer patients participating in 57 clinical trials.
Izvedli so tudi sistemsko ocenjevanje, ki je vključevalo več kot 9 000 bolnikov z rakom, ki so sodelovali v 57 kliničnih preskušanjih.
• you have unstable angina pectoris (new or increasing chest pain)
• če imate nestabilno angino pectoris (nove ali naraščajoče bolečine v prsnem košu)
As with all growth factors, there is a concern that epoetins could stimulate the growth of any type of malignancy.
Kot pri vseh rastnih dejavnikih obstaja tudi pri epoetinih skrb, da lahko stimulirajo rast katerega koli tipa malignosti.
The expiry date refers to the last day of that month.
Datum izteka roka uporabnosti se nanaša na zadnji dan v navedenem mescu.
Do not use this medicine after the expiry date which is stated on the label and the carton.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli.
It is recommended that initial erythroid response be assessed 8 to 12 weeks following initiation of treatment.
Priporočljivo je, da začetni eritroidni odziv ocenimo 8 do 12 tednov po začetku zdravljenja.
For instructions on handling of the medicinal product before administration, see section 6.6.
Za navodila glede ravnanja z zdravilom pred dajanjem glejte poglavje 6.6.
Frequency estimate: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000), not known (frequency cannot be estimated from the available data).
Ocenjena pogostnost: zelo pogosti (>1/10); pogosti (>1/100 do <1/10); občasni (>1/1 000 do <1/100); redki (>1/10 000 do <1/1 000); zelo redki (<1/10 000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
• have severe heart disease
• imate hudo bolezen srca,
Store in a refrigerator (2°C - 8°C).
Shranjujemo v hladilniku (2°C - 8°C).
You will receive appropriate training to enable you to do this.
V ta namen vas bodo primerno izobrazili.
ESAs are not indicated for use in this patient population.
Zdravila ESA niso indicirana za uporabo v tej populaciji bolnikov.
Other causes of PRCA should be excluded, and appropriate therapy initiated.
Druge vzroke za PRCA je treba izključiti in začeti z ustrezno terapijo.
The dose should be administered over at least 1-5 minutes, depending on the total dose.
Odmerek je treba injicirati najmanj 1 do 5 minut, odvisno od celotnega odmerka.
Patients who for any reason cannot receive adequate antithrombotic prophylaxis.
Bolniki, ki iz kakršnegakoli razloga ne morejo prejemati ustrezne profilakse proti trombozi.
Do not to stop the treatment without consultation of your doctor.
Zdravljenja ne prekinjajte brez posveta z zdravnikom.
The therapeutic margin of erythropoietin is very wide.
Terapevtske meje eritropoetina so zelo široke.
The half-life is difficult to evaluate for the subcutaneous route and is estimated to be about 24 hours.
Razpolovni čas je pri subkutanem dajanja težko ovrednotiti, po ocenah naj bi bil okoli 24 ur.
95% CI for Mean Prior Transfusions
95 % IZ za povprečje Predhodne transfuzije
• Problem with the blood that may cause pain, dark coloured urine or increased sensitivity of the skin to sunlight (porphyria)
• Težava s krvjo, ki lahko povzroči bolečino, temno obarvan urin ali zvečanje občutljivosti kože na sončno svetlobo (porfirija).
The apparent molecular weight of erythropoietin is 32 000-40 000 Dalton.
Navidezna molekularna masa eritropoetina je med 32 000 in 40 000 Daltoni.
The protein moiety of the molecule contributes about 58% of total molecular weight and consists of 165 amino acids.
Proteinski del molekule prispeva okoli 58% h končni molekularni masi, sestavlja pa ga 165 amino kislin.
It is not known whether exogenous epoetin zeta is excreted in human milk.
Ni znano, ali se eksogeni epoetin zeta izloča v materino mleko.
• Skin rashes and swelling around the eyes (oedema), which may result from an allergic reaction.
• Kožni izpuščaji in otekanje okoli oči (edem), ki je lahko posledica alergijske reakcije.
There is no accumulation: the levels remain the same, whether they are determined 24 hours after the first injection or 24 hours after the last injection.
Do akumulacije ne prihaja: koncentracije ostajajo enake, če se merijo 24 ur po prvi ali 24 ur po zadnjem injiciranju.
Three were confirmed TVE and in the remaining case (sudden death), the thromboembolic event was not confirmed.
Tri TVE so potrdili, v zadnjem primeru (nenadna smrt) pa tromboemboličnega zapleta niso potrdili.
In order to improve the traceability of erythropoiesis-stimulating agents (ESAs), the name of the prescribed ESA should be clearly recorded (or: stated) in the patient file.
Da bi zagotovili sledljivost zdravil za stimulacijo eritropoeze (ESA - erythropoiesis stimulating agents), mora biti ime ESA jasno zapisano (ali navedeno) v bolnikovi kartoteki.
The dose you receive is based on your body weight in kilograms.
Odmerek, ki ga dobivate, temelji na vaši telesni masi v kilogramih.
The safety and efficacy of epoetin zeta in paediatrics have not been established.
Varnost in učinkovitost epoetina zeta pri pediatričnih bolnikih nista bili dokazani.
A half-life of approximately 6 hours has been reported in children.
Pri otrocih poročajo o razpolovnem času približno 6 ur.
The following maintenance doses were observed in clinical trials after 6 months of treatment.
V kliničnih preskušanjih so po 6 mesecih zdravljenja opazovali naslednje vzdrževalne odmerke.
Your doctor may decide to increase your heparin dose during dialysis.
Vaš zdravnik se lahko odloči za zvišanje odmerka heparina med dializo.
Silapo must not be mixed with other medicinal products (see section 6.2).
Zdravilo Silapo se ne sme mešati z drugimi zdravili (glej poglavje 6.2).
Dose increases and decreases should be done one dosing step at a time (see diagram below).
Odmerek je treba povečevati ali zmanjševati po en odmerni korak naenkrat (glejte diagram spodaj).
Inject the solution as you have been shown by your doctor.
Raztopino injicirajte tako, kot vam je pokazal zdravnik.
These decisions will be influenced by what is causing your anaemia.
Na te odločitve bo vplival vzrok vaše anemije.
Your doctor will use the lowest effective dose to control the symptoms of your anaemia.
Zdravnik bo uporabil najnižji učinkoviti odmerek za nadzorovanje simptomov Vaše anemije.
• Allergic reaction
• Alergijske reakcije.
• It may have been accidentally frozen.
• če je bila po nesreči zamrznjena
Depending on your individual situation a blood transfusion may be preferable.
Glede na vašo osebno situacijo bo morda bolje uporabiti krvno transfuzijo.
Your doctor will decide this.
O tem bo odločil vaš zdravnik.
• Stroke (insufficient blood supply to the brain, which may lead to inability to move one or more limbs on one side of the body, inability to understand or formulate speech, or an inability to see one side of the visual field).
• Možganska kap (nezadostna prekrvljenost možganov, kar lahko povzroči nezmožnost premikanja ene ali več okončin na eni strani telesa, nezmožnost razumevanja ali tvorjenja stavkov ali nezmožnost videti del vidnega polja).
Pharmacotherapeutic group: Other antianaemic preparations, erythropoietin ATC code: B03XA01
Farmakoterapevtska skupina: druga zdravila za zdravljenje anemije, eritropoetin Oznaka ATC: B03XA01
In controlled clinical studies, use of epoetin alfa and other ESAs have shown:
V kontroliranih kliničnih študijah je prišlo pri uporabi epoetina alfa in drugih ESA do:
The rashes may progress to widespread peeling of the skin and life-threatening complications.
Izpuščaji se lahko razvijejo v razširjeno lupljenje kože in življenje ogrožajoče zaplete.
The injections can then be given by a doctor, trained nurse or other health care professional.
Injekcije lahko daje zdravnik, medicinska sestra ali drugo zdravstveno osebje.
What you need to know before you use Silapo
Kaj morate vedeti, preden boste uporabili zdravilo Silapo
There are conflicting reports in the literature regarding whether erythropoietin may play a major role as tumour proliferator.
V literaturi je najti nasprotujoča poročila glede tega, ali eritropoetin igra pomembno vlogo kot tumorski pospeševalec.
The dose for children and adolescents is based on body weight in kilograms.
Odmerek za otroke in mladostnike temelji na telesni masi v kilogramih.
These doses may not be as high as those received initially.
Ti odmerki v primerjavi z začetnimi ne bodo tako visoki.
• can't take medicines to thin the blood
• ne morete jemati zdravil za redčenje krvi.
At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions.
Ko se bolnikom predpiše zdravilo, jim je treba svetovati glede znakov in simptomov ter jih skrbno spremljati glede kožnih reakcij.
The treatment is divided into two stages:
Zdravljenje poteka v dveh stopnjah:
In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer.
Z vidika zgoraj omenjenega bi morala biti transfuzija krvi v nekaterih kliničnih situacijah zdravljenje izbire za obvladovanje anemije pri bolnikih z rakom.
This is given twice a week.
Daje se dvakrat tedensko.
All special warnings and precautions associated with autologous predonation programmes, especially routine volume replacement, should be respected.
Spoštovati je treba vsa opozorila in previdnostne ukrepe v zvezi s programi za avtologno transfuzijo, posebno kar se tiče rutinskega nadomeščanja volumna.
Epoetins are not approved in the management of anaemia associated with hepatitis C.
Epoetini niso odobreni za uporabo pri anemijah, povezanih s hepatitisom C.
For intravenous or subcutaneous use.
Za subkutano in intravensko uporabo.
Adverse Reaction (Preferred Term Level)
Neželeni učinek (priporočeni izraz)
Epoetin zeta is a copy of the human protein erythropoietin and acts in the same way.
Epoetin zeta je kopija človeške beljakovine eritropoetina in deluje na enak način.
The decision to administer recombinant erythropoietins should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context.
Odločitev glede dajanja rekombinantnih eritropoietinov mora temeljiti na oceni koristi in tveganj ob sodelovanju posameznega bolnika, pri tem pa bi bilo treba upoštevati specifično klinično situacijo.
Good injection sites are the top of the thigh and around the tummy (abdomen) but away from the navel.
Dobra mesta za injiciranje so na vrhu stegna in okoli trebuha (abdomna), vendar ne blizu popka.
Mean haemoglobin levels were similar for the two treatment groups throughout the postsurgical period.
Povprečje ravni hemoglobina so bile podobne za obe skupini zdravljenja ves čas obdobja po kirurškem posegu.
Target Hb (10 - 12 g/dl)
Ciljna koncentracija Hb (10-12 g/dl)
If you have these symptoms during injection into the vein, a slower delivery of the injection may help to avoid them in the future.
Če te simptome opazite med injiciranjem v veno, se jih s počasnejšim injiciranjem zdravila v prihodnje morda lahko prepreči.
The syringe is now ready for use.
Injekcijska brizga je sedaj pripravljena za uporabo.
Iron supplements and other blood stimulants may increase the effectiveness of Silapo.
Dodatki železa in drugi spodbujevalci tvorbe krvi lahko povečajo učinkovitost zdravila Silapo.
Your doctor will check on this.
Vaš zdravnik bo to nadziral.
In the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
V štirih, s placebom nadzorovanih, študijah so bila razmerja tveganj za skupno preživetje v razponu od 1,25 in 2,47 v prid kontrolam.
• An increase in levels of small blood cells (called platelets), which are normally involved in the formation of a blood clot may occur, particularly when starting treatment.
• Lahko se zvišajo ravni majhnih krvnih celic (imenovanih ploščice), ki so normalno vključene v nastajanje krvnih strdkov, zlasti ob začetku zdravljenja.
Studies in animals have shown reproduction toxicity (see section 5.3).
Študije na živalih kažejo vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
- increase of blood pressure.
- Zvišanje krvnega tlaka.
This should improve during the course of the treatment.
Tekom zdravljenja naj bi se stanje izboljšalo.
Tell your doctor immediately if you suddenly feel very tired or dizzy or suffer from shortness of breath.
Povejte takoj svojemu zdravniku, če se počutite zelo utrujeni, se vam vrti ali vam zmanjkuje sape.
Factors that should be considered in this assessment should include the type of tumour and its stage; the degree of anaemia; lifeexpectancy; the environment in which the patient is being treated; and patient preference (see section
Dejavnike, ki bi jih morali upoštevati pri tej oceni morajo vključevati tip tumorja in njegov stadij, stopnjo anemičnosti, pričakovano življenjsko dobo, okolje v katerem se bolnika zdravi in prednosti za bolnika (glejte poglavje 5.1).
• High levels of blood potassium which can cause abnormal heart rhythm (this is a very common side effect in patients on dialysis).
• Visoke ravni kalija v krvi, ki lahko povzročijo nenormalni srčni ritem (to je zelo pogost neželeni učinek pri bolnikih na dializi).